Ergomed logo

ERGO - Ergomed News Story

595p 40.0  7.2%

Last Trade - 07/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £287.7m
Enterprise Value £278.9m
Revenue £68.3m
Position in Universe 663rd / 1819

Ergomed plc - Total Voting Rights & Block Listing Return

Wed 1st July, 2020 7:00am
RNS Number : 5881R
Ergomed plc
01 July 2020
 

 PRESS RELEASE

 

 

Total Voting Rights and Block Listing Return

 

Total Voting Rights

Guildford, UK - 1 July 2020: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 30 June 2020 consisted of 48,215,791 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right. 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

Block Listing Six Monthly Return

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

1 January 2020

To:

30 June 2020

Balance of unallotted securities under scheme(s) from previous return:

2,133,959

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

214,502

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,919,457

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

1,500,000 ordinary shares of 1p each - 31 December 2019

Total number of securities in issue at the end of the period

48,215,791 ordinary shares of 1p each

 

Name of contact:

Nick Roberts - Head of Group Reporting

Telephone number of contact:

+44 (0) 1483 503 205

 

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

ergomed@consilium-comms.com

Matthew Neal / Olivia Manser




 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRFLFIERRIIVII
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.